RedHill Biopharma Ltd (RDHL) Cash Funds per Share

Corporate emblem and logo of RedHill Biopharma Ltd (RDHL)

RedHill Biopharma generates revenue from the sale of gastrointestinal therapies, betting on the drug Talicia and oncology research. Partnerships with global distributors help the company scale distribution and advance joint development projects. The cash per share allows for a real-time assessment of the issuer's solvency, where the value 0.58 represents the current metric. The commercial growth stage and the expansion of indications for existing drugs will serve as key revenue drivers.

RedHill Biopharma (RDHL) - Cash per Share from 07/04/2022 to 11/20/2026

Analytical breakdowns for RedHill Biopharma

- stock quotes and analyst forecast:
- cash position and cash flow details:
Comprehensive company analysis:RedHill Biopharma Ltd. (RDHL)
Manufactured product of RedHill Biopharma Ltd.

RedHill Biopharma's independence from macro cycles requires significant reserves to fund clinical trials and drug commercialization. This indicator measures the volume of liquid assets per common share. An increase in this metric confirms strengthening financial stability and a reduction in debt risks. It is critical for investors to maintain a balance between capital security and capital efficiency. By analyzing the cash position per share, one can assess the issuer's real margin of safety.